Brenda Cooper

4.9k total citations · 2 hit papers
133 papers, 3.0k citations indexed

About

Brenda Cooper is a scholar working on Hematology, Oncology and Genetics. According to data from OpenAlex, Brenda Cooper has authored 133 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 71 papers in Hematology, 50 papers in Oncology and 39 papers in Genetics. Recurrent topics in Brenda Cooper's work include Lymphoma Diagnosis and Treatment (35 papers), Acute Myeloid Leukemia Research (34 papers) and Hematopoietic Stem Cell Transplantation (31 papers). Brenda Cooper is often cited by papers focused on Lymphoma Diagnosis and Treatment (35 papers), Acute Myeloid Leukemia Research (34 papers) and Hematopoietic Stem Cell Transplantation (31 papers). Brenda Cooper collaborates with scholars based in United States, Canada and Ireland. Brenda Cooper's co-authors include Hillard M. Lazarus, Stanton L. Gerson, Omer N. Koç, Stephen E. Haynesworth, Arnold I. Caplan, Mary J. Laughlin, Richard J. Creger, H. Kent Holland, Philip L. McCarthy and Andrea Bacigalupo and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Blood.

In The Last Decade

Brenda Cooper

126 papers receiving 3.0k citations

Hit Papers

Rapid Hematopoietic Recovery After Coinfusion of Autologo... 2000 2026 2008 2017 2000 2005 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Rapid Hematopoietic Recovery After Coinfusion of Autologous-Blood Stem Cells and Culture-Expanded Marrow Mesenchymal Stem Cells in Advanced Breast Cancer Patients Receiving High-Dose Chemotherapy
    2000 887 citations Omer N. Koç, Stanton L. Gerson et al. Journal of Clinical Oncology profile →
  2. Cotransplantation of HLA-Identical Sibling Culture-Expanded Mesenchymal Stem Cells and Hematopoietic Stem Cells in Hematologic Malignancy Patients
    2005 607 citations Hillard M. Lazarus, Omer N. Koç et al. profile →

Peers

Brenda Cooper
Kazuo Muroi Japan
R. Willemze Netherlands
Jill Corre France
Chiaki Nakaseko Japan
Damiano Rondelli United States
Umberto Gianelli Italy
Renchi Yang China
Mary L. McMaster United States
Jean‐Pierre Marolleau France
Christoph Walz Germany
Kazuo Muroi Japan
Brenda Cooper
Citations per year, relative to Brenda Cooper Brenda Cooper (= 1×) peers Kazuo Muroi

Countries citing papers authored by Brenda Cooper

Since Specialization
Citations

This map shows the geographic impact of Brenda Cooper's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brenda Cooper with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brenda Cooper more than expected).

Fields of papers citing papers by Brenda Cooper

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brenda Cooper. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brenda Cooper. The network helps show where Brenda Cooper may publish in the future.

Co-authorship network of co-authors of Brenda Cooper

This figure shows the co-authorship network connecting the top 25 collaborators of Brenda Cooper. A scholar is included among the top collaborators of Brenda Cooper based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brenda Cooper. Brenda Cooper is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Assouline, Sarit, Amitkumar Mehta, Walter Hanel, et al.. (2025). Phase I/II Study of Subasumstat (TAK-981) in Combination With Rituximab in Relapsed/Refractory Non-Hodgkin Lymphoma. Clinical Lymphoma Myeloma & Leukemia. 25(11). 788–799.e11. 1 indexed citations
2.
3.
Woost, Philip G., Basem M. William, Brenda Cooper, et al.. (2024). Flow cytometry of DNMT1 as a biomarker of hypomethylating therapies. Cytometry Part B Clinical Cytometry. 106(1). 11–24.
4.
Wang, Jiasheng, Amin Firoozmand, Pingfu Fu, et al.. (2023). Phase I study of intra-osseous co-transplantation of a single-unit cord blood and mesenchymal stromal cells with reduced intensity conditioning regimens. Frontiers in Oncology. 13. 1186532–1186532. 2 indexed citations
5.
Pratz, Keith W., Mohamad Cherry, Jessica K. Altman, et al.. (2023). Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML. Journal of Clinical Oncology. 41(26). 4236–4246. 27 indexed citations
6.
7.
Ahmed, Nausheen, Patricio Rojas, Fahrettin Covut, et al.. (2021). Significant costs and low utilization of stored peripheral blood stem cells for salvage autologous transplant in multiple myeloma patients including those meeting mSMART criteria. Bone Marrow Transplantation. 56(6). 1458–1461. 2 indexed citations
8.
Hill, Brian T., Deepa Jagadeesh, Alex Garcia, et al.. (2020). Results of a Phase I Trial of Lenalidomide, Rituximab (R2) and Ixazomib for Frontline Treatment of High Risk Follicular and Indolent Non-Hodgkin Lymphoma. Blood. 136(Supplement 1). 1–2. 1 indexed citations
9.
Gallogly, Molly, Paolo F. Caimi, Michael Craig, et al.. (2017). A Phase II Study of Midostaurin and 5-Azacitidine for Elderly Patients with Acute Myeloid Leukemia. Blood. 130. 1332–1332. 4 indexed citations
10.
Sundaram, Suchitra, Benjamin Tomlinson, Richard J. Creger, et al.. (2017). Early Cardiovascular Toxicity with Treatment of Follicular Lymphoma Is Associated with Shorter Overall Survival. Blood. 130. 2776–2776. 2 indexed citations
11.
Kindwall‐Keller, Tamila L., Howard Meyerson, Seunghee Margevicius, et al.. (2011). Prospective study of one- vs two-unit umbilical cord blood transplantation following reduced intensity conditioning in adults with hematological malignancies. Bone Marrow Transplantation. 47(7). 924–933. 42 indexed citations
12.
Nock, Charles, Joanna M. Brell, Joseph A. Bokar, et al.. (2009). A phase I study of rebeccamycin analog in combination with oxaliplatin in patients with refractory solid tumors. Investigational New Drugs. 29(1). 126–130. 17 indexed citations
13.
Barr, Paul M., Hillard M. Lazarus, Brenda Cooper, et al.. (2009). Phase II study of bryostatin 1 and vincristine for aggressive non‐Hodgkin lymphoma relapsing after an autologous stem cell transplant. American Journal of Hematology. 84(8). 484–487. 54 indexed citations
14.
Ferenczi, Katalin, et al.. (2008). A Case of CD30+ Nasal Natural Killer/T-Cell Lymphoma. American Journal of Dermatopathology. 30(6). 567–571. 14 indexed citations
15.
Heeckeren, Willem J. van, Laura R. Fanning, Howard Meyerson, et al.. (2007). Influence of human leucocyte antigen disparity and graft lymphocytes on allogeneic engraftment and survival after umbilical cord blood transplant in adults. British Journal of Haematology. 139(3). 464–474. 21 indexed citations
16.
Heeckeren, Willem J. van, Pingfu Fu, Brenda Cooper, et al.. (2005). Randomised comparison of two B‐cell purging protocols for patients with B‐cell non‐Hodgkin lymphoma: in vivo purging with rituximab versus ex vivo purging with CliniMACS CD34+ cell enrichment device. British Journal of Haematology. 132(1). 42–55. 22 indexed citations
17.
Cooper, Brenda, Hillard M. Lazarus, Sylvan B. Green, et al.. (2002). A phase I and pharmacodynamic study of sequential topotecan and etoposide in patients with relapsed or refractory acute myelogenous and lymphoblastic leukemia. Leukemia Research. 27(1). 35–44. 9 indexed citations
18.
Passos‐Coelho, José Luís, John M. Davis, A M Huelskamp, et al.. (1996). Comparative Analysis of Breast Cancer Contamination in Mobilized and Nonmobilized Hematopoietic Grafts. Journal of Hematotherapy. 5(5). 549–552. 11 indexed citations
19.
Lazarus, Hillard M., Richard J. Creger, Rasim Gucalp, et al.. (1996). Cefoperazone/sulbactam versus cefoperazone plus mezlocillin: empiric therapy for febrile, neutropenic bone marrow transplant patients. International Journal of Antimicrobial Agents. 7(2). 85–91. 3 indexed citations
20.
Cooper, Brenda, et al.. (1994). An inflammatory eruption associated with recombinant human IL-6. British Journal of Dermatology. 130(4). 534–536. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kazuo Muroi Breakdown of academic impact, for papers by R. Willemze Breakdown of academic impact, for papers by Jill Corre Breakdown of academic impact, for papers by Chiaki Nakaseko Breakdown of academic impact, for papers by Damiano Rondelli Breakdown of academic impact, for papers by Umberto Gianelli Breakdown of academic impact, for papers by Renchi Yang Breakdown of academic impact, for papers by Mary L. McMaster Breakdown of academic impact, for papers by Jean‐Pierre Marolleau Breakdown of academic impact, for papers by Christoph Walz
Rankless by CCL
2026